Publicaciones en las que colabora con Bruno Carlos Sangro Gómez-Acebo (77)

2017

  1. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  2. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 776-783

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

2014

  1. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives

    Expert Opinion on Investigational Drugs, Vol. 22, Núm. 7, pp. 827-841

  3. Increased liver stiffness values in patients with heart failure

    Acta Gastro-Enterologica Belgica, Vol. 76, Núm. 2, pp. 246-250

  4. Prognostic factors and prevention of radioembolization-induced liver disease

    Hepatology, Vol. 57, Núm. 3, pp. 1078-1087

  5. Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure

    PLoS ONE, Vol. 8, Núm. 1

2011

  1. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma

    Functional and Integrative Genomics, Vol. 11, Núm. 3, pp. 419-429

  2. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

  3. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages

    Annals of Surgical Oncology, Vol. 18, Núm. 7, pp. 1964-1971

  4. Transarterial therapies for hepatocellular carcinoma

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 7, pp. 1057-1073

2010

  1. A phase i clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma

    Cancer Gene Therapy, Vol. 17, Núm. 12, pp. 837-843

  2. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma

    International Journal of Radiation Oncology Biology Physics, Vol. 77, Núm. 5, pp. 1441-1448

  3. Gene therapy for liver cancer: Clinical experience and future prospects

    Current Opinion in Molecular Therapeutics, Vol. 12, Núm. 5, pp. 561-569

2009

  1. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma

    Hepato-Gastroenterology, Vol. 56, Núm. 96, pp. 1683-1688

  2. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report

    Clinical Transplantation, Vol. 23, Núm. 4, pp. 532-536

  3. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy

    Cancer Research, Vol. 69, Núm. 4, pp. 1358-1367